Community Acquired Pneumonia (CAP) Market Research Report: Market size, Industry outlook, Market Forecast, Demand Analysis,Market Share, Market Report 2018-2023
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Community Acquired Pneumonia (CAP) Market
Community Acquired Pneumonia (CAP) Market: By Testing & Diagnosis (Chest X-ray/radiography, Sputum Gram stain and/or culture, Blood Cultures), By Therapies & Drugs, By Patient Age group & By Geography - Forecast(2018 - 2023)
Report Code : HCR 0128
Updated Date: 31 May, 2018  

1. Community Acquired Pneumonia (CAP) Market Overview 
2. Executive Summary  
3. Community Acquired Pneumonia (CAP) Market Landscape 
   3.1. Market Share Analysis 
   3.2. Comparative Analysis 
      3.2.1. End-User Profiling 
      3.2.2. Financial Analysis of Top 5 Players 
4. Community Acquired Pneumonia (CAP) Market Forces 
   4.1. Market Drivers 
   4.2. Market Constraints 
   4.3. Market Challenges  
   4.4. Attractiveness of Industry  
      4.4.1. Power of Supplier 
      4.4.2. Power of Consumer 
      4.4.3. Threat of New Entrants 
      4.4.4. Threat of Substitution 
      4.4.5. Degree of Competition 
5. Community Acquired Pneumonia (CAP) Market Strategic Analysis 
   5.1. Value Chain Analysis 
   5.2. Pricing Analysis  
   5.3. Opportunity Analysis 
   5.4. Product Life Cycle Analysis  
   5.5. Suppliers & Distributors 
6. Community Acquired Pneumonia (CAP) Market- By Testing & Diagnosis 
   6.1. Chest X-ray/radiography 
   6.2. Sputum Gram stain and/or culture 
   6.3. Blood Cultures 
   6.4. Others 
      6.4.1. COMPLETE BLOOD CELL (CBC) COUNT  
      6.4.2. SERUM SODIUM LEVEL 
      6.4.3. SERUM BLOOD UREA NITROGEN (BUN) AND CREATININE LEVELS 
      6.4.4. SERUM TRANSAMINASE LEVELS 
      6.4.5. SERUM PHOSPHORUS LEVEL 
      6.4.6. LACTIC ACID LEVEL 
      6.4.7. CREATINE PHOSPHOKINASE (CPK) 
      6.4.8. C-REACTIVE PROTEIN (CRP) 
      6.4.9. LACTATE DEHYDROGENASE (LDH) 
      6.4.10. PROCALCITONIN 
      6.4.11. COLD AGGLUTININ TITERS 
      6.4.12. URINARY ANTIGEN TESTING  
      6.4.13. SEROLOGIC STUDIES FOR M PNEUMONIAE 
      6.4.14. POLYMERASE CHAIN REACTION (PCR) TESTING 
7. Community Acquired Pneumonia (CAP) Market- By Therapies & Drugs 
   7.1. Antiviral Threapy 
      7.1.1. RIBAVIRIN 
      7.1.2. OSELTAMIVIR 
      7.1.3. ZANAMIVIR 
      7.1.4. ACYCLOVIR 
   7.2. Antibiotic Threapy 
      7.1.1. AMOXICILLIN 
      7.1.2. AZITHROMYCIN OR CLARITHROMYCIN 
      7.1.3. AMPICILLIN 
      7.1.4. VANCOMYCIN OR CLINDAMYCIN 
      7.1.5. CEFTRIAXONE OR CEFOTAXIME 
      7.1.6. GENTAMICIN 
8. Community Acquired Pneumonia (CAP) Market- By Drugs provided to different age groups 
   8.1. Newborns 
      8.1.1. AMPICILLIN 
      8.1.2. GENTAMICIN 
   8.2. Children 
      8.2.1. AMOXICILLIN 
      8.2.2. CEFPODOXIME 
      8.2.3. AMPICILLIN 
      8.2.4. CEFTRIAXONE OR CEFOTAXIME 
   8.3. Adults 
      8.3.1. AZITHROMYCIN OR CLARITHROMYCIN 
      8.3.2. CEFPODOXIME 
      8.3.3. AMOXICILLIN 
      8.3.4. CEFTRIAXONE OR CEFOTAXIME 
9. Community Acquired Pneumonia (CAP) Market- By Geography 
   9.1. North America 
      9.1.1. The U.S. 
      9.1.2. Canada 
      9.1.3. Rest of North America 
   9.2. Europe 
      9.2.1. The U.K. 
      9.2.2. Germany 
      9.2.3. France 
      9.2.4. Italy 
      9.2.5. Rest of Europe 
   9.3. Asia-Pacific 
      9.3.1. China 
      9.3.2. India 
      9.3.3. Japan 
      9.3.4. Rest of APAC 
   9.4. Latin America 
      9.4.1. Brazil
      9.4.2. Argentina 
      9.4.3. Mexico 
      9.4.4. Rest of Latin America 
   9.5. Rest of the World 
      9.5.1. The Middle East 
      9.5.2. Africa 
10. Community Acquired Pneumonia (CAP) Market Entropy 
   10.1. New Product Launches 
   10.2. M&As, Collaborations, Partnerships & JVs 
11. Company Profiles (Overview, Financials, Products & Services, Recent Developments, Competitors & Customers) 
   11.1. Pfizer 
   11.2. Astrazeneca Plc. 
   11.3. Bioaegis Therapeutics, Inc. 
   11.4. Biotest AG 
   11.5. C10 Pharma AS 
   11.6. Kyorin Pharmaceutical Co., Ltd 
   11.7. Melinta Therapeutics, Inc 
   11.8. Merck & Co., Inc. 
   11.9. NABRIVA THERAPEUTICS AG 
   11.10. Paratek Pharmaceuticals, Inc 
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
12. Appendix 
   12.1. Abbreviations 
   12.2. Sources 
   12.3. Research Methodology 
   12.4. Bibliography 
   12.5. Compilation of Expert Insights 
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll